BERLDRG
New to Zerodha? Sign-up for free.
New to Zerodha? Sign-up for free.
-
Share Price
-
Financials
-
Revenue mix
-
Shareholdings
-
Peers
-
Forensics
- 5D
- 1M
- 6M
- YTD
- 1Y
- 5Y
- MAX
This data is currently unavailable for this company.
-
Summary
-
Profit & Loss
-
Balance sheet
-
Cashflow
This data is currently unavailable for this company.
| (In Cr.) |
|---|
| (In Cr.) | ||||
|---|---|---|---|---|
|
This data is currently unavailable for this company. |
| (In %) |
|---|
| (In Cr.) |
|---|
| Financial Year (In Cr.) |
|---|
-
Product wise
-
Location wise
Revenue Mix
This data is currently unavailable for this company.
Revenue Mix
This data is currently unavailable for this company.
Recent events
-
News
-
Corporate Actions
This data is currently unavailable for this company.
Events:
More Nano Cap Ideas
See similar 'Nano' cap companies with recent activity
Promoter Buying
Companies where the promoters are bullish
Capex
Companies investing on expansion
Superstar Investor
Companies where well known investors have invested
Popular questions
-
Business
-
Financials
-
Share Price
-
Shareholdings
What does Beryl Drugs do?
Beryl Drugs Limited, established in 1993, specializes in pharmaceutical manufacturing with a global presence offering research, development, contract manufacturing, and veterinary products.
Who are the competitors of Beryl Drugs?
Beryl Drugs major competitors are Unjha Formulations, Parmax Pharma, Colinz Laboratories, Shamrock Indl. Co, Ortin Global, Ganga Pharma., Adline Chem Lab. Market Cap of Beryl Drugs is ₹12 Crs. While the median market cap of its peers are ₹10 Crs.
Is Beryl Drugs financially stable compared to its competitors?
Beryl Drugs seems to be less financially stable compared to its competitors. Altman Z score of Beryl Drugs is 3.04 and is ranked 4 out of its 8 competitors.
Does Beryl Drugs pay decent dividends?
The company seems to be paying a very low dividend. Investors need to see where the company is allocating its profits. Beryl Drugs latest dividend payout ratio is 0% and 3yr average dividend payout ratio is 0%
How has Beryl Drugs allocated its funds?
Companies resources are allocated to majorly productive assets like Plant & Machinery and unproductive assets like Inventory, Accounts Receivable
How strong is Beryl Drugs balance sheet?
Balance sheet of Beryl Drugs is strong. It shouldn't have solvency or liquidity issues.
Is the profitablity of Beryl Drugs improving?
The profit is oscillating. The profit of Beryl Drugs is ₹0.77 Crs for Mar 2024, ₹0.77 Crs for Mar 2023 and -₹0.66 Crs for Mar 2022
Is the debt of Beryl Drugs increasing or decreasing?
The net debt of Beryl Drugs is decreasing. Latest net debt of Beryl Drugs is ₹3.26 Crs as of Mar-25. This is less than Mar-24 when it was ₹4.75 Crs.
Is Beryl Drugs stock expensive?
Beryl Drugs is expensive when considering the PE ratio, however latest EV/EBIDTA is < 3 yr avg EV/EBIDTA. Latest PE of Beryl Drugs is 53.22, while 3 year average PE is 25.08. Also latest EV/EBITDA of Beryl Drugs is 6.92 while 3yr average is 8.59.
Has the share price of Beryl Drugs grown faster than its competition?
Beryl Drugs has given better returns compared to its competitors. Beryl Drugs has grown at ~37.7% over the last 3yrs while peers have grown at a median rate of 8.82%
Is the promoter bullish about Beryl Drugs?
Promoters stake in the company seems stable, and we need to go through filings and allocation of resources to gauge promoter bullishness. Latest quarter promoter holding in Beryl Drugs is 26.38% and last quarter promoter holding is 26.38%.
Are mutual funds buying/selling Beryl Drugs?
There is Insufficient data to gauge this.
